The invention provides methods for treating brain insulin resistance and/or diseases associated therewith in a subject in need thereof. The methods include providing a composition comprising a dual GLP-1 receptor/GIP receptor (GLP-1R/GIPR) agonist and administering an effective amount of the composition to the subject to treat brain insulin resistance and diseases associated therewith.